Corvus Pharmaceuticals, Inc. (CRVS) has a negative trailing P/E of -76.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 129.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -1.30%, forward earnings yield 0.77%.
Criteria proven by this page:
Overall SharesGrow Score: 57/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -6.1 | -0.11 | 1.66 | 0.00 | - |
| 2017 | -3.8 | -0.25 | 2.50 | 0.00 | - |
| 2018 | -2.2 | 0.06 | 0.92 | 0.00 | - |
| 2019 | -3.4 | 0.27 | 2.25 | 0.00 | - |
| 2020 | -17.5 | 0.20 | 1.45 | 0.00 | - |
| 2021 | -2.3 | -0.01 | 1.04 | 0.00 | - |
| 2022 | -1.0 | 0.07 | 0.71 | 0.00 | - |
| 2023 | -3.1 | 0.09 | 2.18 | 0.00 | - |
| 2024 | -5.2 | -0.06 | 10.02 | 0.00 | - |
| 2025 | -39.8 | 0.49 | 9.93 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-2.36 | $0.00 | $-36.38M | - |
| 2017 | $-2.72 | $0.00 | $-55.66M | - |
| 2018 | $-1.71 | $0.00 | $-46.94M | - |
| 2019 | $-1.49 | $0.00 | $-46.67M | - |
| 2020 | $-0.16 | $0.00 | $-6M | - |
| 2021 | $-1.03 | $0.00 | $-43.24M | - |
| 2022 | $-0.89 | $0.00 | $-41.31M | - |
| 2023 | $-0.56 | $0.00 | $-27.03M | - |
| 2024 | $-1.02 | $0.00 | $-62.29M | - |
| 2025 | $-0.53 | $0.00 | $-15.28M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.69 | $-0.97 – $-0.56 | $1.18M | $1.02M – $1.34M | 5 |
| 2027 | $-0.78 | $-0.86 – $-0.69 | $20.84M | $18.07M – $23.6M | 4 |
| 2028 | $-0.64 | $-1.56 – $0.05 | $58.15M | $50.44M – $65.87M | 6 |
| 2029 | $-0.46 | $-0.53 – $-0.38 | $130.1M | $112.85M – $147.36M | 4 |
| 2030 | $0.12 | $0.10 – $0.14 | $235.81M | $204.53M – $267.1M | 2 |
